KCFPF

Medications

Medications for Idiopathic Pulmonary Fibrosis

Prior to FDA approval of OFEV and Esbriet

After DA approval of OFEV and Esbriet

In Oct 2014, the FDA approved Esbriet® (pirfenidone) and OFEV® (nintedanib) for treatment of Idiopathic Pulmonary Fibrosis. These drugs are not a cure for Pulmonary Fibrosis but they slow down the progression of scarring in the lungs.

Genentech makes Esbriet. Go to Genentech website for more information.

Boehringer Ingelheim makes OFEV. Go to Boehringer Ingelheim website for more information.

Talk with your doctor to see if Esbriet or OFEV is right for you. The use of Esbriet and OFEV for various Pulmonary Fibrosis diagnosis are expanding every day.

Medications for Interstitial Lung Diseases

Treatment for scleroderma or systemic sclerosis interstitial lung disease:

OFEV is a treatment option for scleroderma lung disease. The FDA approved OFEV on Sep 6, 2019.

https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-patients-rare-type-lung-disease

https://www.ofev.com/scleroderma-ild

On March 4, 2021, the FDA approves Genentech’s Actemra for Slowing the Rate of Decline in Pulmonary Function in Adults with Systemic Sclerosis-Associated Interstitial Lung Disease.

https://www.gene.com/media/press-releases/14897/2021-03-04/genentechs-actemra-becomes-the-first-bio?fbclid=IwAR3nMXnZFvM3xgOpNkLzEFK232eDOCADFYpO99AKziX3ICnAc2P0JsqtEKk

Also, Pulmonologists prescribe other medication such Prednisone. In the middle of the Pulmonary Fibrosis Foundation Treatment Options website page discusses various other medications.